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Effects of repeated annual influenza 
vaccination on vaccine sero-response in 
young and elderly adults 
W.E.P. Beyer*, A.M. Palache*, M.J.W. Sprenger’f, E. HendriksenS, 
J.J. Tukkers, R. Dariolil, G.L. van der Water*, N. Masurel* and 
A.D.M.E. Osterhaus*ll 
Three cohort studies in adults were performed during the periode from 1986 to 1989. Eight 
hundred and eighty-four subjects were, one or more times, immunized with inf?uenzu 
vaccines, and pre- and post-vaccination antibody titres were determined by hemagglutina- 
tion inhibition tests. One thousand and one hundred and nineteen vaccination events in 681 
subjects could be analysed by a comparison, per trial andper influenza (sub) type, between 
groups with and without influenza vaccination in previous years. Eflect size, odds ratio and 
protection rate deference, were used as e#ect measures. Subjects with previous vaccination 
showed higher pre-vaccination antibody than those without. The average change of the 
post-vaccination proportion of subjects with high antibody titre value to previous 
vaccination, was +9.4% (95% CI: +5.3 to 13.6%) for A-H3N2 vaccine components, 
-2.1% (-8.1 to 3.9%, not significant) for A-HlNl and -10.6% (-16.5% to -4.8%) 
for B. In a linear regression model, pre-vaccination titres and the status of previous 
vaccination were identified as factors signt$cantly influencing post-vaccination titres. 
These findings are discussed in the context of a short review of the literature. It is 
concluded that the status of previous vaccination should always be addressed as an 
independent factor in serological vaccination studies. Copyright 0 1996 Elsevier Science 
Ltd. 
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Active immunization with inactivated vaccines against 
influenza virus types A and B in subjects at risk of 
developing serious complications after influenza infec- 
tion, has been advised to be repeated annually to comply 
with antigenic drift of the viruses and decrease of 
antibody levels with time. This policy, however, has been 
questioned by field studies in the 197Os, which suggested 
a decrease of protective immunity upon annually re- 
peated vaccination’-3. Although the methods of these 
studies have been criticized4 and more recent studies5-7 
have not confirmed these findings, the value of annual 
influenza vaccination still remains a subject of 
discussion. 
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Field vaccination studies are difficult to perform due 
to the poor predictability of influenza outbreaks, which 
makes power-calculations troublesome. The most 
important parameters of efficacy are reduction of 
mortality and severe morbidity which may not occur 
frequently thus requiring large numbers of participants 
in efficacy trials. Moreover, since a beneficial effect of 
influenza vaccination has been established, it is no 
longer ethically acceptable to perform double-blind, 
prospective field studies in groups at risk of developing 
serious complications. Therefore. serological studies 
with hemagglutination inhibition (HI) serum antibody 
titres as a surrogate marker for real vaccine efficacy, 
are usually performed, with divergent results: some- 
times a lower7.‘, and sometimes a higher’ post- 
vaccination serum antibody titre was observed in 
subjects with a vaccination history when compared to 
those not vaccinated before, and in other studies, 
post-vaccination antibody titres were not significantly 
affected by previous vaccinationss,‘0-‘7. 
Here we present the results of three different cohort 
studies, performed in primed populations during an 
inter-pandemic period (19861989) with low activity of 
naturally occurring influenza. 
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Table 1 Vaccines used in three trial cohort studies 
YA AE RE 
Season Composition Type” Dosage @g HA) Type Dosage &g HA) Type Dosage bg HA) 
1986 
1987 
1988 
1989 
A/Mississippi/l/85 (H3N2) 
A/Chile/l/83 
B/Ann Arbor/l/86 
A/Taiwan/l/86 (Hl Nl) 
AfLeningrad/360/86 (ki3N2) 
A/Taiwan/l/86 (HlNl) 
B/Ann Arbor/l/86 
AJSichuanl2187 (H3N2) 
AJTaiwanllJ86 (HlNl) 
BJBeyingil f87 
AJShanghai/ll/87 (H3N2) 
A/Taiwan/l/86 (HlNl) 
BJYamagataJl6l87 
su 
SU 
su 
10 or 20b su 10 WV 10 or 20c 
10 or 20 10 lOor 
10 or 20 15 15or30 
15 or 30 
10 su 10 WV 10 
10 10 10 
10 10 15 
10 su 10 WV 10 
10 10 10 
10 10 10 
su 10 WV 10 
10 10 
10 10 
WV, whole virus vaccine; SU, subunit vaccine. ‘A dose response trial with two dosages. “Dosage scheme, including booster vaccinations, 
described in Ref. 14 
MATERIALS AND METHODS 
Vaccinees and trials 
The first two cohort studies (designated YA, young 
adults, and AE, ambulatory elderly) were part of open 
vaccination studies to comply with regulatory require- 
ments, as described elsewhere13. Young, clinically 
healthy adults were recruited from medical schools 
and other teaching institutions in The Netherlands. 
Ambulatory elderly with (70%) or without (30%) age- 
related chronic diseases, were recruited from a general 
geriatric outpatients’ department in Switzerland. Before 
intake, previous vaccinations against influenza were 
documented. In total, 237 young adult and 221 elderly 
subjects were vaccinated once or more times in the 
period from 1986 to 1989, respectively. During the study 
period, no cases of influenza-like illness (ILI) were 
reported by the vaccinees. 
The third cohort study (designated RE. resident 
elderly) took place in a Dutch rural nursing home with 
275 beds (135 for somatic patients and 140 for psycho- 
geriatric patients). Before 1986, only a few patients 
received influenza vaccine on their own request. But. 
when in January/February 1986 a large influenza 
A-H3N2 epidemic affected 103 of the patients (37%)14, 
general vaccinations were performed every year since 
autumn 1986. The annual vaccination rate in the nursing 
home varied between 7 1 and 8 l%, involving 426 patients 
who were vaccinated once or more times between 1986 
and 1989. Most of these subjects (97%) were older than 
60 years of age at the moment of first vaccination. The 
vaccination history of new entries could not always be 
traced back in patients with dementia. In March 1989 a 
small epidemic of IL1 occurred in 19 patients (influenza 
B serologically confirmed in seven patients). 
All volunteers (or in case of dementia, their relatives) 
gave informed consent to participate in the trials. 
For the cohort studies YA and AE, Medical Ethical 
Committee approval was obtained. 
For this study, vaccinees were selected according to 
the following post-hoc criteria: 
(1) Age: In cohort studies AE and RE only subjects 
born in 1927 or earlier were included; in cohort 
study YA only subjects born after 1927 were 
included. 
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(2) 
(3) 
(4) 
History of previous vaccinations: Subjects who, at 
the entry of the cohort studies, recorded previous 
vaccinations against influenza within the last 
5 years, were excluded. Moreover, subjects who 
were repeatedly vaccinated in the course of a 
cohort study, were included if the vaccination 
sequence was not interrupted by a year without 
vaccination. For example, a subject vaccinated in 
1987 and 1989, but not in 1988, was included in the 
trial 1987, but not in 1989. 
Lack of effect group: The trials of 1986 were not 
included in the serological analysis as they all 
consisted of not previously vaccinated subjects (i.e. 
no comparison according to status of previous 
vaccinations possible). 
Complete serology: Subjects with incomplete either 
pre- or post-vaccination sera due to lack of com- 
pliance or organization mistakes, or subjects with 
less than 15 days between pre- and post-vaccination 
serum, or subjects with missing titres for either 
serum or either vaccine component due to labora- 
tory limitations, were excluded from the actual trial 
(but not necessarily from the following trials). 
Vaccine preparations and doses 
Inactivated influenza vaccines (Influvac whole-virus 
vaccine, Influvac subunit vaccine; Solvay-Duphar BV, 
Weesp, The Netherlands) contained strains of influenza 
A-H3N2, A-HlNl and B, according to the annual 
recommendations of the World Health Organization. As 
shown in Table 1, the A-HlNl component remained 
unchanged for most years while the A-H3N2 and B 
components were replaced by new variants every 1 or 
2 years. The influenza vaccine type was whole-virus for 
cohort study RE, and subunit for cohort studies YA and 
AE. Vaccine doses varied between 10 and 15 ,ug HA per 
strain, except for two dose-response trials in 1986. 
Vaccines were administered intramuscularly or deep 
subcutaneously. 
Serological methods 
Serum specimens were collected prior to vaccination 
(pre-vaccination serum) and again after at least 15 days 
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(post-vaccination serum). Samples were stored frozen 
prior to laboratory determinations of homologous 
hemagglutination-inhibition (HI) antibody titres. All 
sera of a trial were titrated simultaneously and in 
duplicate. Cohort studies YA and AE were titrated in 
the laboratory of Solvay-Duphar, with a test-antigen 
concentration of 4-8 hemagglutination units (HAU)“, 
without ether-treatment of influenza B test-antigen. 
With this method, protection is supposed to be associ- 
ated with a titre of 240 (influenza A) and 220 (influ- 
enza B). Negative sera (no inhibition in a 1:8 dilution) 
were arbitrarily recorded as 4 for calculations. Cohort 
study RE was titrated at the National Influenza Centre, 
by a similar method, but with a lower test-antigen 
concentration of 3 HAU16, and with ether-treatment of 
influenza B test-antigen”; this method produced high 
absolute titres and was described as being associated 
with a protection threshold of 2 100 (influenza A)18 and 
2200 (influenza B)19. Negative sera (no inhibition in a 
1:9 dilution) were arbitrarily recorded as 5. Titre values 
were transformed to decadic logarithms. 
Association of the “protection thresholds” (40/20 or 
100/200) with real protection is controversial. For con- 
venience, we called subjects surpassing the appropriate 
titre thresholds “protected subjects”, rather than 
“subjects with high antibody titre”. 
Statistical methods 
As titrations were performed separately per trial, no 
comparisons could be made between, but only within 
trials. Per trial and per vaccine component, pre- and 
post-vaccination geometric mean titres (pre-GMT, post- 
GMT), and pre- and post-vaccination proportions of 
protected subjects (pre-PR, post-PR) were calculated for 
subgroups with previous vaccination (effect groups) and 
without previous vaccination (control groups). 
Per trial and per vaccine component, the effect of 
previous vaccination was estimated by measuring the 
differences between effect and control groups. Three 
effect measures were calculated: 
(1) 
(2) 
(3) 
Effect size (Es) (according to Dawson-Saunders 
et ul.‘“), defined as: 
ES=(GMT, - GMT,)/S.D.,,,,,,. 
where GMT, and GMT, represent he geometric 
mean titres of the control and effect groups, 
respectively, and S.D.rooled is the pooled standard 
deviation. 
Logarithm of odds ratio (O.R.), defined as: 
ln0. R. =ln(A+O.5)*(D+O.5)l((B+0.5)*(C+0.5)). 
where A and C are the numbers of protected 
subjects in the control and effect groups, respect- 
ively, and B and D are the numbers of not pro- 
tected subjects in control and effect group, 
respectively. 
Rate difference (RD), defined as: 
RD=PR, - PR,. 
where PR, and PR, are the proportions of pro- 
tected subjects in the control and effect groups, 
respectively. 
ES-, In 0. R.- and RD-values are 0 in case of no 
difference between effect and control group (i.e. no effect 
of previous vaccination); they are positive in case of 
higher titres or percentage of protection in the group 
with previous vaccinations, compared to the control 
group, and vice versa. The calculation of 95% confidence 
intervals allows to define the significance of the effect 
measures. 
Per (sub)type, effect measures from all trials were 
pooled by a one-step technique of meta-analysis as 
described previously (Yusuf-Peto modified Cochran- 
Mantel-Haenzel method”) resulting in pooled values 
for influenza A-H3N2, A-HlNI and B, respectively. The 
validity of the pooling procedure was tested by a xz-test 
for homogeneity between trials, according to Breslow 
and Day”. 
Per trial and per vaccine component, post-GMT were 
subjected to linear regression with status of previous 
vaccinations (i.e. 0 for control groups, 1 for effect 
groups) as independent variable. In a first model of 
linear regression also other factors were included as 
independent variables: pre-vaccination titre, year of 
birth, gender, days between vaccination and drawing 01 
post-vaccination blood specimen, number of previous 
vaccinations (one to three times), underlying diseases 
(for cohort studies AE and RE), vaccine dosages in 1986 
(for cohort studies YA and RE), and clinically or 
virologically confirmed IL1 in January/February 1986 
and March 1989 (for cohort study RE). In a consecutive 
model, only those factors were included which signifi- 
cantly contributed to post-vaccination GMT in the 
first model. In a similar procedure, post-vaccination 
percentages of protection were subjected to logistic 
regression. 
For all statistical procedures, a P-value of 0.05 or 
less was considered to indicate statistical significance. 
Calculations were done on a personal computer using a 
statistical software package (SPSS/PC+4.0; Microsoft 
Corporation, Redmond/Washington, USA). 
RESULTS 
Final numbers of vaccinees with complete serology 
As shown in Table 2, in three cohort studies 1715 
vaccinations were performed, involving 884 subjects 
who were vaccinated once or more times during the 
period from 1986 to 1989. After applying the post-hoc 
selection criteria described in Materials and Methods, 
1119 paired sera of 681 subjects entered the analysis: in 
cohort study YA, 181 subjects with a mean year of birth 
of 1963 (range 1942-1969) and a percentage of male 
subjects of 44, in cohort study AE, 198 subjects with a 
mean year of birth of 1913 (1892-1927) and 47% male 
subjects, and in cohort study RE, 298 subjects with a 
mean year of birth of 1906 (1889-1927) and 27% male 
subjects. Table 2 also presents 
subjects per trial, according to 
vaccinations. 
the numbers of selected 
the number of previous 
Pre- and post-vaccination titres 
Figure I presents pre- and post-vaccination GMT- 
values and proportions of protected subjects according 
to influenza (sub)types, trials and status of previous 
vaccination. Per trial, pre-GMT and pre-PR were, in 
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Table 2 Numbers of vaccinees, and exclusions from serological analysis 
Triala 
Total 
number of Excluded for No No Number of previous vaccinations 
vaccinees Excluded previous effect complete Selected 
per trial for age vaccinations group serology vaccinees 0 1 2 3 
YA 1986 143 3 140 
1987 130 5 7 118 25 93 
1988 149 4 2 143 63 18 62 
AE 1986 63 10 53 
1987 116 10 3 103 40 63 
1988 139 10 3 126 54 28 44 
1989 113 6 6 101 41 0 22 38 
RE 1986 234 7 4 223 
1987 209 6 4 z5 194 59 135 
1988 196 5 7 159 40 25 94 
1989 223 10 16 22 175 64 18 19 74 
All trials 1715 28 79 416 73 1119 386 380 241 112 
No. subject@ 884 13 21 127 42 681 
“YA, young adults; AE, ambulatory elderly; RE, resident elderly. *Numbers of subjects are smaller than numbers of vaccination events (all trials) 
as a part of the subjects was vaccinated more than once 
Fig. 1.1 A-H3N2 A-H1 Nl B 
YOUNG AMBULATORY RESIDENT 
ADULTS ELDERLY ELDERLY 
1997 1988 1987 1999 1999 1997 1989 1999 
Fig. 1.2 A-H3N2 A-H1 Nl 
% PROT YOUNG AMBULATORY RESIDENT ADULTS ELDERLY ELbERLY 
0101010101010101 
PREVAC 
B 
1987 1988 1987 1988 1989 1987 1988 1989 
Figure 1 Pre- and post-vaccination mean titres, and proportions of protected subjects, according to trial and status of previous vaccination. 
(1.1) shows the geometric mean titres (GMT), (1.2) the proportion of protected subjects (% PROT). The whole bar represents the 
post-vaccination titre (1 .l), or the post-vaccination proportion of protected subjects (1.2); the lower part of the bar represents the pre-vaccination 
titre, or the pre-vaccination proportion of protected subjects. T, upper 95% confidence limit of post-vaccination titre (1 .l); PREVAC, status of 
previous vaccination (0, control group-not previously vaccinated; 1, effect group-previously vaccinated) 
virtually all cases, higher in previously vaccinated 
groups than in the control groups, regardless of the 
age-class and the antigenic resemblance of the consecu- 
tive virus strains per (sub)type. Post-GMT and post-PR 
were much less uniform: In previously vaccinated 
groups, in some cases these variables were higher, in 
other cases lower than the respective control groups. For 
the influenza A strains, no large differences could be 
detected in most cases. For influenza B, however, there 
appeared a general tendency to lower post-GMT and 
post-PR in groups with previous vaccination. 
Effect measures 
Figure 2 showing three different effect measures 
according to trial and (sub)type, reveals that the 
generally positive effect of previous vaccination on pre- 
vaccination titres was significant in the majority of trials. 
Only one trial (RE 1989 for influenza B) had an insig- 
nificantly lower percentage of protected subjects pre- 
viously vaccinated compared to the control group. 
In contrast, a clear-cut effect of previous vaccination on 
the post-vaccination status was not present: most val- 
ues, either positive or negative, were not significantly 
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YAl907J 
1988 
AE1987 
1988 
1989 
RE1987 
1988 
1989 
YA1987 
1988 
AE1987 
1988 
1989 
RE1987 
1988 
1989 
YA1987 
1988 
AE1987 
1988 
1989 
RE1987 
1988 
1989 
I 
-2 
YA1987 
1988 
AE1987 
1988 
1989 
RE1987 
1988 
1989 
YA1987 
1988 
AE1987 
1988 
1989 
RE1987 
1988 
1989 
YA1987 
1988 
AE1987 
1988 
1989 
RE1987 
1988 
1989 
-8 
YA1987 
1988 
AE1987 
1988 
1989 
RE1987 
1988 
1989 
YA1987 
1988 
AE1987 
1988 
1989 
RE1987 
1988 
1989 
YA1987 
1988 
AI51987 
1988 
1989 
RE1987 
1988 
1989 
Pm-vaccination titre 
-l A-H3N2 
A-HlNl 
A-H3N2 
A-HI Nl 
/ 
8 
Post-vaccination titre 
r 
1 2 
4 8 
Fig. 2.2 
In Odds Ratio 
(InOF?) 
Fig. 2.3 
rate difference 
(W 
Fig. 2.1 
effect size 
(ES) 
Figure 2 Effect measures (with 95% Cls) according to trial and (sub)type. YA, young adults: AE, ambulatory elderly; RE, resident elderly 
different from zero. ES-values varied between -0.99 This impression was confirmed, for both pre- and 
and +0.51, In O.R.-values between -2.38 and +2.90, post-vaccination titres, by pooling the effect measures of 
and RD-values between -23.6% and +24.6%. It ap- all eight trials according to (sub)types (Figure 3). In all 
peared, however, that there were differences between 18 comparisons, influenza A-H3N2 had higher values 
(sub)types: A-H3NZvalues were generally higher than than influenza B, with A-HINI in an intermediate 
B-values. position. For pre-vaccination titres, this sequence did 
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Pre-vaccination titre Post-vaccination titre 
A-H3N2 
A-H1 Nl 
Fig. 3.1 
pooled ES 
-1.5 -1 -0.5 0 0 5 1 1.5 -1.5 -1 -0.5 0 0.5 I 1.5 
Fig. 3.2 
pooled InOR 
-3 -2 -1 0 1 2 3 
LiEI 
Fig. 3.3 
A-H3N2 Do&d RD 
A-H1 Nl 4 
B 
i / 
-30 -20 -10 0 10 20 30 -30 -20 -10 0 IO 20 30 
Figure 3 Pooled effect measures (with 95% Cls), according to (sub)type. ES, effect size; In O.R., logarithm of odds ratio; RD, rate difference 
not lead to a qualitative difference between (sub)types: 
all pooled effect measures were significantly positive. 
The average additional effect of previous vaccination on 
pre-vaccination proportion of protected subjects (Figure 
3c) was +22.3% for A-H3N2, +15.8% for A-HlNl and 
+4.2% for B. In contrast, the pooled effect measures of 
post-vaccination titres were positive only for A-H3N2 
(pooled In O.R. and RD even significantly so), negative 
but very close to zero for A-H lN1, and significantly 
negative for B. In other words, on average previous 
vaccination is associated with higher post-vaccination 
titres for A-H3N2 vaccine components, compared with 
not previously vaccinated subjects, and with lower titres 
for B components. There is no such effect for the 
A-HlNl component. The average increase of the post- 
vaccination proportion of protected subjects, due to 
previous vaccination, was +9.4% (95% CI: +5.3 to 
+13.6%), the average decrease for B was - 10.6% 
(-16.5to -4.8%),andforA-HlNl -2.1%(-8.1%to 
+3.9%) (Figure 3c). 
Variables influencing post-vaccination titres 
Per trial and (sub)type, and in part within relevant 
subpopulations, post-vaccination titres and post- 
vaccination protection were subjected to linear regres- 
sion and logistic regression, respectively, including a 
number of independent variables. Year of birth within 
the given range of the cohort study (2 1928 for YA, 
cl928 for AE and RE), gender, days between vaccina- 
tion and drawing of post-vaccination blood specimen, 
number of previous vaccinations, underlying diseases 
(for cohort studies AE and RE), vaccine dosages in 
1986 (for cohort study YA and RE), and clinically or 
virologically confirmed illness in January/February 1986 
and March 1989 (for cohort study RE) did not show a 
significant contribution to post-vaccination titres. In all 
comparisons, the pre-vaccination titre was the strongest 
predictor of the post-vaccination status. In most com- 
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parisons, also status of previous vaccination contributed 
significantly to post-vaccination titres. 
Linear regression on post-vaccination titres was re- 
peated with only pre-vaccination titres and status of 
previous vaccination as independent factors. The result- 
ing regression coefficients for both factors are shown in 
Table 3. Ail regression coefficients for pre-vaccination 
titre were significantly 0, confirming the well-known 
strong positive linear relationship between pre- and 
post-vaccination titres. Regression coefficients for the 
status of previous vaccination, all but one, were 
negative. The addition of an interaction term (the 
product of pre-vaccination titre and status of previous 
vaccinations) did not improve the model. 
DISCUSSION 
The first main result of our paper concerns the pre- 
vaccination titres: they are generally higher in effect 
groups (previously vaccinated) than in control groups 
(not previously vaccinated). This finding is biologically 
plausible (persistence of vaccine-induced antibody) and 
has been previously described in other papers5.7-12.‘7. 
Our second main finding, on post-vaccination titres, is 
not clear-cut: post-vaccination titres of effect groups can 
be higher than, equal to, or lower than those in control 
groups. When pooling the effect measures of all trials 
according to (sub)type, we saw a tendency to higher 
post-vaccination titres for the A-H3N2 vaccine compo- 
nents, the opposite for B components and virtually no 
effect for A-HlNl. This also implies that the sequence of 
consecutive vaccine-strains in the period 19861989 had 
obviously no influence. The (sub)type difference of effect 
measures is not reflected by the fact that both A-H3N2 
and B vaccine components changed more frequently 
than the A-HI Nl component. 
In this paper, we examined three different study 
populations. Age differences could have affected the 
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Table 3 Linear regression of pre-vaccination titre and status of previous vaccinations on post-vaccination titre per (sub)type and trial 
(SWyw Triala 
Pre-vaccination titre Status of previous vaccination* 
Regression coefficient 
H3N2 YA 
AE 
HlNl 
RE 
YA 
AE 
RE 
YA 
AE 
RE 
1987 
1988 
1987 
1988 
1989 
1988 
1989 
1987 
1988 
1987 
1988 
1989 
1987 
1988 
1989 
1987 
1988 
1987 
1988 
1989 
1987 
1988 
1989 
0.707 <0.0001 
0.787 <0.0001 
0.783 <0.0001 
1.037 <0.0001 
0.744 <0.0001 
0.352 <0.0001 
0.703 <0.0001 
0.625 <0.0001 
0.595 <0.0001 
0.635 <0.0001 
0.662 <0.0001 
0.869 <0.0001 
0.990 <0.0001 
0.538 <0.0001 
0.634 <0.0001 
0.467 <0.0001 
0.646 <0.0001 
0.713 <0.0001 
0.732 <0.0001 
0.714 <0.0001 
1.503 <0.0001 
0.519 <0.0001 
0.484 <0.0001 
0.545 <0.0001 
P-value Regression coefficient P-value 
-0.339 
-0.180 
-0.406 
-0.434 
-0.360 
0.019 
-0.161 
-0.199 
-0.274 
-0.433 
-0.464 
-0.409 
-0.354 
-0.199 
-0.230 
-0.317 
-0.488 
-0.464 
-0.351 
-0.518 
-0.411 
-0.178 
-0.262 
-0.166 
<0.0001 
0.0010 
10.0001 
<0.0001 
0.0010 
0.8429 
0.0987 
0.0571 
0.0111 
<0.0001 
<0.0001 
<0.0001 
0.0005 
0.0334 
0.0320 
0.0020 
<0.0001 
<0.0001 
0.0002 
<0.0001 
0.0004 
0.0058 
0.0099 
0.0656 
?‘A, young adults; AE, ambulatory elderly; RE, resident elderly. bStatus of previous vaccination: 0 for not previously vaccinated; 1 for previously 
vaccinated 
effect measures, both by mechanisms of biological follow-up would have been statistically stronger, but 
ageing of the immune system (decrease of sero- only possible for the A-HlNl strain A/Taiwan/l/86 
responsiveness, for review see Refs 23,24), and the which remained in the vaccine composition during the 
influenza-specific phenomenon of “original antigenic 
sin”2s. 
whole study period, while the A-H3N2 and B com- 
Figure 2 reveals, however, that there are no real ponents were replaced by new strains every 1 or 2 years. 
differences between the effect measures of the cohort Our approach, a comparison of effect and control 
studies YA (young adults, most of whom born after groups strictly per trial, allowed to ignore the 
1957) and AE (ambulatory elderly, born in 1927 or between-trial differences of A-H3N2 and B components, 
earlier). In particular this was true for influenza and the differences due to titration methods. A possible 
A-HlNl, the subtype of which the seroresponse is statistical inferiority, compared with individual follow- 
usually strongest affected by the original antigenic sin as 
it had disappeared in 1957 and reappeared in 197726. 
up, may have been compensated by the large number of 
data (1119 paired sera). 
Other differences between our study populations 
concern the influenza vaccine types (subunit vaccine in 
YA and AE, whole-virus vaccine in RE), and the 
epidemiological characteristics: RE consisted of a semi- 
closed community (nursing home), while the vaccinees 
of AE and YA belonged to the general, epidemio- 
logically open, population. Natural influenza, like the 
A-H3N2 epidemic in RE in 1986, has a much stronger 
impact in semi-closed communities which may modulate 
the response on vaccination in the following years. 
However, we did not find, by regression analysis, any 
such influence in our data. Another difference may be 
that the groups of previously not-vaccinated subjects 
were better defined in AE and YA than in RE where 
subjects with previous vaccination outside the nursing 
home could not always be identified because of the high 
proportion of dementia. We believe that the combined 
influence of all these population characteristics did not 
seriously affect our outcome measures, as can be derived 
from the only small inter-trial variation (Figure 2). 
Serum titrations were done per trial, on different 
points of time, in two different laboratories, and with 
different protocols of the HI test. This approach did not 
allow for comparisons between trials, and specially not 
for the follow-up of those individuals who had partici- 
pated during the whole study period. Such an individual 
To compare our finding on post-vaccination titres 
with the international literature, we identified nine 
papers wherein rate differences could be calculated. 
Table 4 shows the results of, in total, 34 comparisons. In 
26 comparisons, rate differences were not significantly 
different from zero (i.e. no effect of previous vac- 
cination). In two comparisons, rate differences were 
significantly higher in the effect groups (one time 
A-H3N2, one time A-HlNl), and in six comparisons 
rate differences were significantly lower (one time 
A-H3N2, two times A-HlNl, three times B). Of special 
interest were the studies of Govaert et aZ.’ and Glathe 
et a1.9. Both studies were performed in the same year (i.e. 
identical strains) with the same vaccine type (split-virus). 
Nevertheless, Govaert et al. saw a strong negative effect 
for all three (sub)types, and Glathe et al. a strong 
positive effect for the A-strains. Although the results of 
Govaert et al. may be more reliable than those of Glathe 
et al. because of larger numbers of vaccinees (906 vs 92) 
and a more consistent statistical analysis, this extreme 
heterogeneity is remarkable. 
We saw in our data that an individual post- 
vaccination titre is strongly dependent on the pre- 
vaccination titre and, inversely, on the status of previous 
vaccination. The linear relationship between pre- and 
post-vaccination titre is well known29. The inverse 
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Table 4 Review of the literature: effect of previous vaccinations on post-vaccination percentage of protected subjects 
Post-vaccination rate difference (95% Cl) per (sub)type (%)” 
First author Year of trial Number of vaccinees A-H3N2 A-H1 Nl B 
Powersb 1981 
Power@ 1981182 
Keitel” 1983 
KeitelC 1984 
Petersd 1985 
Gross’ 1986 
Beyer’ 1987 
McElhaneyg 1991 
Govaert” 1991 
Glathe’ 1991 
PyhW 1991 
Pyhblti’ 1992 
This paper Pooled data 
52 -11.5 (-24.2-1.1) 11.5 (-7.0-30.1) 7.7 (-9.7-25.1) 
70 2.9 (-2.7-8.4) 8.6 (-5.5-22.6) 0.0 (-7.8-7.8) 
3091316 1.6 (-12.8-9.5) -0.9 (-8.2-6.3) -8.0 (-16.3-0.3) 
4571461 6.9 (-16.3-2.5) -9.9 (-19.) -0.6) -3.1 (-6.5-0.2) 
131 <o 
140 0.6 (-19.1-20.3) -10.0 (-30.7-10.7) -1.5 (-20.2-17.2) 
108 8.7 (-28.1-10.8) -5.5 (-23.4-12.5) -20.5 (-38.7- -2.2) 
26 *O *O *O 
906 -18.4 (-27.4- -9.3) -26.6 (-36.2- -17.0) -32.4 (-42.0- -22.7) 
92 14.7 (5.1-24.3) 17.1 (4.6-29.7) 5.4 (-4.2-15.0) 
33 -6.9 (-41 .l-27.2) -1.4 (-26.4-23.6) 1.4 (-29.9-32.7) 
45 1.5 (-22.4-25.5) 4.5 (-17.9-27.0) -7.6 (-35.0-l 9.9) 
9.4 (5.3-13.6) -2.1 (-8.1-3.9) -10.6 (-16.4- -4.8) 
aRate difference (RD), difference between the proportions of protected subjects of effect group (previously vaccinated) and control group (not 
previously vaccinated). Significant RDvalues bold. *Powers et a/.“, In a time-cohort study, immunized 18-65-year-old healthy adults with 
whole-virus vaccine containing A/Bangkok/l/79 (H3N2), A/Brazil/ll/78 (HlNl) and B/Singapore/222/79 (7.5 or 15 pg HA per strain) three times 
with time-intervals of 6 months. Protective titre threshold: 40. Data estimated from Fig. 1 and Fig. 2 of the paper, with “1st vaccina0on” as control 
group, and “2nd vaccination” as effect group. Data on the third vaccination not included. ‘Keitel et aL5 immunized 30-60-year-old adults with 
whole-virus vaccine containing A/Philippines/2/82 (H3N2), A/Brazil/l l/i’8 (Hl Nl) and B/Singapore/222/79, or placebo, in 1983, and with 
A/Philippines/2/82 (H3N2), A/Chile/l/83 (Hl Nl), and B/USSR/100/83, or placebo, in 1984 (15 pg HA per strain). Protective titre threshold: 32. 
Data derived from Tables 1 and 2 of the paper. Data on placebo not included. dPeters et a/.’ described a dose response trial in elderly subjects 
with a whole-virus vaccine containing A/Philippines/2/82 (H3N2), A/Chile/l/83 (HlNl), and B/USSR/100/83 (15 pg HA per strain), or 
B/USSR/100183 (45 fig HA) alone. They did not present percentages of protection for groups previously and not previously vaccinated, but 
showed that post-vaccination GMT for the influenza B vaccine component was significantly lower in previously vaccinated subjects, compared 
to those not previously vaccinated. This finding was indicated by the symbol “<O” in this table. eGross et al.” immunized 65-96-year-old healthy 
ambulatory and institutionalized elderly adults with split-virus vaccine containing A/Mississippi/l/85 (H3N2), AfChileill83 (Hl Nl) and B/Ann 
Arbor/l/86 (15 pg HA per strain). Protective titre threshold: 40. Data derived from Table 3 of the paper. Data on a smaller group receiving also 
AfTaiwan/l/86 (HlNl) 1 month later, not included. ‘Beyer et a/.” vaccinated patients on chronic intermittent haemodialysis with whole-virus 
vaccine containing A/Leningrad/360/86 (H3N2), &Taiwan/l/86 (Hl Nl) and B/Ann Arbor/l/86 (10, 10, and 15 pg HA). Protective titre threshold: 
100 for influenza A, 200 for influenza B. The publication presented data on the effect of previous vaccinations as “mean fold increase”. Original 
raw data were re-analysed for this paper. WcElhaney et a/.” studied whole- and split-virus vaccines containing A/Beijing/353/89 (H3N2), 
A/Taiwan/l/86 (Hl Nl) and B/Panama/45/90, in young and elderly adults; they did not present data on previous vaccinations but stated that 
“subgroup analysis showed that previous vaccination had no effect on the response to the different strains measured in the study” (p. 1059). 
This finding was indicated by the symbol “*O” (i.e. not significantly different from 0) in this table. “Govaert et a/.’ immunized 60-91-year-old 
healthy ambulatory elderly adults with split-virus vaccine containing A/Beijing/353/89 (H3N2), A/Taiwan/l/86 (Hl Nl), B/Panama/45/90 and 
B/Beijing/l/87 (15 ,ug HA per strain). Protective titre threshold: 100 for influenza A, 200 for influenza B. Data derived from Table 10.3 of the paper. 
Data on the second B-strain not included. ‘Glathe et a/.’ compared the seroresponse to a split-virus vaccine containing A/Beijing/353/89 (H3N2), 
maiwan/l/86 (HlNl) and B/Yamagata/l6/88 (15 rug HA per strain), in five groups of young and elderly adults with different proportions of 
previous vaccinations. Protective titre threshold: 40. Authors did not perform a statistical analysis on the effect of previous vaccination. Data 
derived from Tables 2-4 of the paper, with “Group A” (not previously vaccinated subjects) as control group, and “Group E” (95% previously 
vaccinated) as effect group. Data on groups B to D (26%-45% previously vaccinated) not included. ‘Pyh&lP et a/. ‘*followed three groups of adult 
volunteers (25-59 years of age) during 1990-1992. The split-virus vaccine contained, in 1991, A/Beijing/353/89 (H3N2), PJTaiwanll/86 (HlNl) 
and B/Panama/45/90, and in 1992, A/Beijing/353/89 (H3N2), A/Taiwan/l/86 (Hl Nl) and B/Yamagata/l6/88 (15pg HA per strain). Protective titre 
threshold: 40. Data were derived from Table 2 of the paper, with “group 1” as effect group and “group 2” as control group in 1991, and “group 
1” and “group 2” as pooled effect group and “group 3” as control group in 1992. Data for A/Taiwan/l/86 (Hl Nl) and B/Panama/45/90 were not 
given. Calculations are based on data for AIFinland/l64/91 (HlNl) and B/Yamagata/l6/88 
relationship between status of previous vaccination and 
post-vaccination titre has already been seen by Peters 
et al.’ and Pyhlla et aE.28 At a given pre-vaccination 
titre, the post-vaccination titre can be expected to be 
lower in previously vaccinated subjects than in not 
previously vaccinated subjects. Thus, natural antibody, 
caused by previous infections, has a larger potential to 
form high post-vaccination titres, than the same amount 
of vaccine-induced antibody3’. 
The biological interpretation of the inverse relation- 
ship between status of previous vaccination and post- 
vaccination titre is troublesome. The phenomenon 
could be described as a “negative booster effect of 
previous vaccinations” suggesting an active immuno- 
logical feed-back mechanism which inhibits the produc- 
tion of additional post-vaccination antibody. It has also 
been pointed out that natural and vaccine-induced 
antibody may differ in their IgA- and IgG-subclass 
composition or their ratio of strain-specific and cross- 
reacting components which are not differentiated by the 
HI-test. It is also possible that the inverse relationship is 
a pure “mathematical artifact” in the sense that post- 
vaccination antibody may reach a plateau after first 
vaccination which can not be exceeded by repeated 
vaccinations. Since at the same time pre-vaccination 
titre is higher after repeated vaccination, a negative 
coefficient for repeated vaccinations occurs in the 
regression equation which has no biological meaning 
at all. 
It should be underlined that our data were based on 
the HI-titre, i.e. a surrogate marker for real vaccine 
efficacy. In high concentrations, the HI-titre is a good 
marker, or in other words: a vaccine which induces high 
HI-titres, is undoubtedly a highly effective means to 
prevent serious influenza illness. On the other side, a 
vaccine, which induces low HI-titre should not auto- 
matically be regarded as inferior if it stimulates other 
immunological measures which are also protective even 
without high HI-titres. Therefore, our finding that, 
specially in cohort studies AE and YA, post-vaccination 
HI-antibody decreased after annually repeated vaccina- 
tion for the influenza B component, does not necessarily 
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mean that real protection against natural influenza B 
evenly decreased in these groups. In studies which 
recorded natural infections in groups with and without 
repeated vaccinations, subjects with previous vaccina- 
tion showed an equal or even greater protection against 
natural influenza compared to those without’-‘. 
Thus, while annually repeated influenza vaccination 
has probably no negative clinical impact, it should 
always be included as an independent factor in 
serological vaccination studies. 
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